<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02903004</url>
  </required_header>
  <id_info>
    <org_study_id>INT 181/15</org_study_id>
    <nct_id>NCT02903004</nct_id>
  </id_info>
  <brief_title>Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients _MITO-23</brief_title>
  <acronym>Mito23</acronym>
  <official_title>Randomized Phase III Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype patients_MITO-23</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione IRCCS Istituto Nazionale dei Tumori, Milano</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, prospective, multicenter, randomized Phase III, clinical trial
      evaluating the efficacy and safety of trabectedin in BRCA1 and BRCA2 mutation carrier and
      BRCAness phenotype advanced ovarian cancer patients in comparison to physician' choice
      chemotherapy.

      Arm A: Trabectedin 1.3 mg/mq d1 q 21 in 3 hours (central line) Arm B: Pegylated Liposomal
      Doxorubicin 40 mg/mq q 28 or Topotecan 4 mg/mq dd 1,8,15 q 28 or Gemcitabine 1000 mg/mq dd 1,
      8, 15 q 28 Weekly Paclitaxel 80 mg/mq gg 1, 8, 15 q 28 Carboplatin AUC 5-6 q 21 or 28

      Patients will be randomly assigned in a 1:1 ratio to treatment arms. During the randomization
      process, patients will be stratified by

        -  Platinum sensitivity

        -  Measurable disease

        -  Number of previous chemotherapy lines &gt; vs &lt; 3

        -  BRCA mutational status
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomized in a 1:1 ratio to receive one of the following treatments: Arm A:
      Trabectedin 1.3 mg/m2 d1 q 21 in 3 hours (central line) Arm B: Pegylated Liposomal
      Doxorubicin 40 mg/mq q 28 or Topotecan 4 mg/ m2 dd 1,8,15 q 28 or Gemcitabine 1000 mg/mq dd
      1, 8, 15 q 28 Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28 Carboplatin AUC 5-6 q 21 or 28
      Randomization will be stratified based on platinum-free interval (PFI) (PFI ≥ 0 and ≤ 6
      months vs. PFI &gt; 6 months), presence / absence of measurable disease/number of previous
      chemotherapy lines, germline BRCA mutational status vs BRCAness phenotype.

      Platinum-free interval (PFI) is defined as the time from the last dose of the platinum
      containing regimen until the first date progression.

      Subjects will continue to receive chemotherapy treatment until disease progression (clinical
      progression meant as global deterioration in health status attributable to the disease
      requiring a change in therapy without objective evidence of progression is considered
      progression of disease), intolerability, patient refusal, investigator decision or death from
      any cause.

      Subjects will be evaluated every 12 weeks ± 1 week by Response Evaluation Criteria in Solid
      Tumors (RECIST 1.1) for objective radiographic response and radiographic disease progression.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>4 years</time_frame>
    <description>The primary objective is to compare the Trabectedin versus physician' choice chemotherapy in terms of overall survival (OS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>4 years</time_frame>
    <description>Progression-free survival [the diagnosis of progression will be assessed by radiological criteria; CA 125 increases alone (GCIG criteria of progression) will not be considered as progression of disease without a radiological confirmation of progression].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>4 years</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>4 years</time_frame>
    <description>Incidence of adverse events, according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 4.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">244</enrollment>
  <condition>Ovarian Neoplasms</condition>
  <arm_group>
    <arm_group_label>Trabectedin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trabectedin 1.3 mg/m2 d1 q 21 in 3 hours (central line)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Treatment</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Pegylated Liposomal Doxorubicin 40 mg/mq q 28 or Topotecan 4 mg/ m2 dd 1,8,15 q 28 or Gemcitabine 1000 mg/mq dd 1, 8, 15 q 28 Weekly Paclitaxel 80 mg/ m2 dd 1, 8, 15 q 28 Carboplatin AUC 5-6 q 21 or 28</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trabectedin</intervention_name>
    <arm_group_label>Trabectedin</arm_group_label>
    <other_name>Yondelis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Liposomal Doxorubicin</intervention_name>
    <arm_group_label>Standard Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <arm_group_label>Standard Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Standard Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Weekly Paclitaxel</intervention_name>
    <arm_group_label>Standard Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Standard Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female of age 18 years or older

          2. Histologically or cytologically documented invasive epithelial ovarian cancer, primary
             peritoneal carcinoma, or fallopian tube cancer

          3. Platinum resistant or sensitive patients with either:

               1. BRCA mutated patients

               2. BRCAness phenotype patients: patients who have received and responded (subsequent
                  PFI&gt;6 months) to at least 2 previous platinum based chemotherapy lines

               3. Platinum sensitive patients who are not able to receive or not willing to receive
                  other platinum treatments

          4. Measurable and evaluable disease per RECIST 1.1(Subjects with isolated rising CA-125
             without radiologically visible disease are excluded)

          5. ECOG performance status 0 or 1

          6. No limits in the number of previous chemotherapy lines, previous treatment with parp
             inhibitors is allowed

          7. Left Ventricular Ejection Fraction (LVEF) ≥ institutional lower limit normal

          8. Life expectancy of at least 3 months

          9. Adequate organ functions:

               1. Hematopoietic: Absolute neutrophil count ≥ 1,500/mm3; Platelet count ≥
                  100,000/mm3; Hemoglobin ≥ 9 g/dl

               2. Hepatic: AST and ALT ≤ 1.5 times upper limit of normal (ULN)* ; Alkaline
                  Phosphatase ≤ 2.5 times ULN* ; Bilirubin ≤ 1.5 times ULN. NOTE: * ≤ 3 times ULN
                  if liver metastases are present

               3. Renal: Creatinine Clearance ≥ 45 ml/min or Serum Creatinine ≤1.5 x ULN

               4. Serum Albumin &gt;2.5 g/dl

         10. No other invasive malignancy within the past 3 years except non-melanoma skin cancer
             or in situ cervical cancer (patients with previous cancers may be enrolled providing
             that no recurrences have be reported in the last 3 years)

         11. Written Informed Consent

         12. Adequately recovered from the acute toxicity of any prior treatment

         13. For agents in the standard arm, also refer to the local prescribing information with
             regards to warnings, precautions, and contraindications

        Exclusion Criteria:

          1. Prior exposure to trabectedin

          2. Known hypersensitivity to any of the components of the trabectedin i.v. formulation or
             dexamethasone

          3. Subjects with borderline ovarian cancer, ie. Subject with low malignant potential
             tumors are excluded

          4. Less than 2 reported responses to platinum (i.e. subsequent recurrences at least 6
             months after the first and the second platinum based treatment), unless BRCA mutation
             is documented.

          5. Less than 4 weeks from last dose of therapy with any investigational agent, or
             chemotherapy

          6. History of another neoplastic disease (except basal cell carcinoma or cervical
             carcinoma in situ adequately treated) unless in remission for 3 years or longer

          7. Known clinically relevant CNS metastases, unless treated and asymptomatic

          8. Other serious illnesses, such as:

               1. Congestive heart failure or angina pectoris; myocardial infarction within 1 year
                  before enrolment; uncontrolled arterial hypertension or arrhythmias.

               2. Psychiatric disorder that prevents compliance with protocol.

               3. Active viral hepatitis; or chronic liver disease.

               4. Active infection.

               5. Any other unstable medical conditions.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Domenica Lorusso, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Istituto Nazionale Tumori</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Domenica Lorusso, MD</last_name>
    <phone>+390223903697</phone>
    <email>domenica.lorusso@istitutotumori.mi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elisa Grassi</last_name>
    <phone>+390223903818</phone>
    <email>trialcenter@istitutotumori.mi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Domenica Lorusso</name>
      <address>
        <city>Milan</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domenica Lorusso, MD</last_name>
      <phone>+390223903697</phone>
      <email>domenica.lorusso@istitutotumori.mi.it</email>
    </contact>
    <contact_backup>
      <last_name>Elisa Grassi</last_name>
      <phone>+390223903818</phone>
      <email>elisa.grassi@istitutotumori.mi.it</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Salutari V, Ferrandina G, Vincenzi B et al. Efficacy and safety outcomes in heavily pretreated patients (pts) with relapsed ovarian cancer (roc ) after single agent trabectedin. ASCO 2013, submitted.</citation>
  </reference>
  <reference>
    <citation>Monk BJ, Herzog T, Kay S et al. A randomized Phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC). Ann. Oncol. 19(Suppl. 8), (2009)</citation>
  </reference>
  <reference>
    <citation>K. L. Tedesco, J. L. Blum, A. Goncalves, J. Lubinski, N. Ben-Baruch, C. R. Osborne, P. Lardelli, A et al. phase II trial of trabectedin (T) in patients (pts) with HER2-positive and BRCA1/2 germ-line-mutated metastatic breast cancer (MBC). J Clin Oncol 28:15s, 2010 (suppl; abstr 1038)</citation>
  </reference>
  <results_reference>
    <citation>Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, Kraemer KH, Pommier Y. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001 Aug;7(8):961-6. Erratum in: Nat Med 2001 Nov;7(11):1255.</citation>
    <PMID>11479630</PMID>
  </results_reference>
  <results_reference>
    <citation>Damia G, Silvestri S, Carrassa L, Filiberti L, Faircloth GT, Liberi G, Foiani M, D'Incalci M. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways. Int J Cancer. 2001 May 15;92(4):583-8.</citation>
    <PMID>11304695</PMID>
  </results_reference>
  <results_reference>
    <citation>Schöffski P, Taron M, Jimeno J, Grosso F, Sanfilipio R, Casali PG, Le Cesne A, Jones RL, Blay JY, Poveda A, Maki RG, Nieto A, Tercero JC, Rosell R. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer. 2011 May;47(7):1006-12. doi: 10.1016/j.ejca.2011.01.016. Epub 2011 Mar 4.</citation>
    <PMID>21376569</PMID>
  </results_reference>
  <results_reference>
    <citation>Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, Beltrame L, Marchini S, Fuso Nerini I, Sanfilippo R, Casali PG, Pilotti S, Galmarini CM, Anichini A, Mantovani A, D'Incalci M, Allavena P. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013 Feb 11;23(2):249-62. doi: 10.1016/j.ccr.2013.01.008.</citation>
    <PMID>23410977</PMID>
  </results_reference>
  <results_reference>
    <citation>del Campo JM, Sessa C, Krasner CN, Vermorken JB, Colombo N, Kaye S, Gore M, Zintl P, Gómez J, Parekh T, Park YC, McMeekin S. Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials. Med Oncol. 2013 Mar;30(1):435. doi: 10.1007/s12032-012-0435-1. Epub 2013 Feb 9.</citation>
    <PMID>23397080</PMID>
  </results_reference>
  <results_reference>
    <citation>Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, D'Incalci M. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer. 2001 Jan;37(1):97-105.</citation>
    <PMID>11165136</PMID>
  </results_reference>
  <results_reference>
    <citation>Herrero AB, Martín-Castellanos C, Marco E, Gago F, Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 2006 Aug 15;66(16):8155-62.</citation>
    <PMID>16912194</PMID>
  </results_reference>
  <results_reference>
    <citation>Safra T, Borgato L, Nicoletto MO, Rolnitzky L, Pelles-Avraham S, Geva R, Donach ME, Curtin J, Novetsky A, Grenader T, Lai WC, Gabizon A, Boyd L, Muggia F. BRCA mutation status and determinant of outcome in women with recurrent epithelial ovarian cancer treated with pegylated liposomal doxorubicin. Mol Cancer Ther. 2011 Oct;10(10):2000-7. doi: 10.1158/1535-7163.MCT-11-0272. Epub 2011 Aug 11.</citation>
    <PMID>21835933</PMID>
  </results_reference>
  <results_reference>
    <citation>Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16.</citation>
    <PMID>10655437</PMID>
  </results_reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Trabectedin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

